SCHEMBL25424630

SCHEMBL25424630

Nc1cnn(Cc2cnc(N3CCC3)nc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ BTK Q06187 2/20 0.36
▸ BCL2L1 Q07817 1/20 0.34
▸ KLKB1 P03952 2/20 0.34
▸ TAAR1 Q96RJ0 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ DRD2 P14416 1/20 0.32
▸ DRD4 P21917 1/20 0.32
▸ DRD3 P35462 1/20 0.32
▸ SCD O00767 1/20 0.31
▸ SCD5 Q86SK9 1/20 0.31
▸ DHFR P00374 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25263910 0.81 MAPT (0.51) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL31075273 0.80 L3MBTL1 (0.46) LMNAL3MBTL1ALDH1A1PKMBTK
SCHEMBL29390128 0.79 BTK (0.41) MAPTLMNAALDH1A1BTKKLKB1
SCHEMBL26969840 0.78 KLKB1 (0.41) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL26969965 0.78 MAPT (0.48) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL30708788 0.78 KLKB1 (0.41) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL30708864 0.75 MEN1 (0.40) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL30708743 0.75 MAPT (0.39) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL30708789 0.75 MAPT (0.41) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL26969996 0.75 MEN1 (0.40) MAPTLMNAMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4210694-B1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-10-15 — — EP disclosed
US-20230416227-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-12-28 — — US disclosed
EP-4210694-A1 PLASMA KALLIKREIN INHIBITORS Merck Sharp & Dohme LLC (US) 2023-07-19 — — EP disclosed
WO-2022056051-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416227-A1 PLASMA KALLIKREIN INHIBITORS KLKB1, SERPINE1, KLK5 MAPT 781/4885LMNA 2426/4885MEN1 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback